These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34195552)

  • 1. Estimated Public Health Impact of the Recombinant Zoster Vaccine.
    Patterson BJ; Buck PO; Curran D; Van Oorschot D; Carrico J; Herring WL; Zhang Y; Stoddard JJ
    Mayo Clin Proc Innov Qual Outcomes; 2021 Jun; 5(3):596-604. PubMed ID: 34195552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
    Oh H; Tan C; Williams C; Giannelos N; Ng C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
    van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
    BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
    Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy.
    Volpi A; Boccalini S; Dari S; Clarke C; Curran D; Loiacono I; Pitrelli A; Puggina A; Tosatto R; Van Oorschot D; Franco E
    Hum Vaccin Immunother; 2020; 16(2):327-334. PubMed ID: 31442095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing.
    Lee C; Jiang N; Tang H; Ye C; Yuan Y; Curran D
    Hum Vaccin Immunother; 2021 Oct; 17(10):3735-3746. PubMed ID: 34310268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
    Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
    Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
    Curran D; Patterson B; Varghese L; Van Oorschot D; Buck P; Carrico J; Hicks K; Lee B; Yawn B
    Vaccine; 2018 Aug; 36(33):5037-5045. PubMed ID: 30017145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis.
    Watanabe D; Mizukami A; Holl K; Curran D; Van Oorschot D; Varghese L; Shiragami M
    Dermatol Ther (Heidelb); 2018 Jun; 8(2):269-284. PubMed ID: 29680914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the Public Health Burden of Herpes Zoster and the Impact of Adjuvanted Recombinant Zoster Vaccine in Five Selected Countries in Southeast Asia.
    Han R; San Martin P; Ahmed N; Guzman-Holst A; Mohy A; Pinto T; de Veras B; Gomez JA; Bibera GL; van Oorschot DAM
    Infect Dis Ther; 2024 Apr; 13(4):761-778. PubMed ID: 38493411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
    McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
    Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
    Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
    Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain.
    García A; Vallejo-Aparicio LA; Cambronero Martinez R
    Hum Vaccin Immunother; 2024 Dec; 20(1):2366353. PubMed ID: 38925145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.